Pharming Group Company Description

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally.

The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3Kẟ inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.

It also develops OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE.

The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105.

Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.

Pharming Group N.V.

Country	Netherlands
Founded	1988
Industry	Biotechnology
Sector	Healthcare
Employees	382
CEO	Sijmen de Vries

Contact Details

Address: Darwinweg 24 Leiden, 2333 CR Netherlands
Phone	31 71 524 7400
Website	pharming.com

Stock Details

Ticker Symbol	PHARM
Exchange	Euronext Amsterdam
Fiscal Year	January - December
Reporting Currency	USD
ISIN Number	NL0010391025
SIC Code	2836

Key Executives

Name	Position
Dr. Sijmen de Vries M.B.A., M.D.	President, Chief Executive Officer and Executive Director
Jeroen Wakkerman	Chief Financial Officer
Mireille Sanders M.Sc.	Chief Operations Officer
Susanne Embleton	Investor Relations Manager
Ruud Van Outersterp	Chief Ethics and Compliance Officer
Dr. Anurag Relan M.D., MPH	Chief Medical Officer
Stephen Toor	Chief Commercial Officer and GM Americas
Dr. Alexander Breidenbach M.B.A.	Chief Business Officer
Dr. Bruno M. L. Giannetti	Consultant